NeuFluent

Name

NeuFluent

Legal name

NeuFluent

Website

https://neufluent.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Neuroscience Venture Studio / Neurotechnology

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical and Medical Instrument Manufacturing (339112)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAFAKAK

Neurodiagnostic Centers (EEG/EMG/NCS)

Healthcare & Life Sciences/Healthcare Providers & Systems/Diagnostic & Imaging Centers

SECONDARYHLAFAMAL

Clinical Research & Trial Central Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

Keywords

• Neuroscience venture studio
• Neurotechnology development
• Brain-computer interfaces
• Neurological medical devices
• AI drug delivery

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Venture Studio Model: NeuFluent operates as a neuroscience innovation venture studio that partners with leading innovators to accelerate breakthrough neurological technologies from concept to market. The studio generates value through equity stakes in portfolio companies and commercialization of developed technologies.
2. Technology Development and Commercialization: Development of next-generation healthcare technologies including brain-computer interfaces, pharmaceutical technology, intelligent implants and robotics, and clinical intelligence solutions that are then commercialized through various channels.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

NeuFluent is a neuroscience innovation venture studio that partners with leading innovators to develop and commercialize breakthrough neurological technologies from concept to market. It operates four initiatives — Brain-Computer Interfaces, Pharmaceutical Technology, Intelligent Implants & Robotics, and Clinical Intelligence — and integrates neuroscience, engineering, regulatory, manufacturing, and commercialization expertise under one roof, monetizing through licensing, equity stakes, and commercialization partnerships rather than direct product sales.

Product overview

NeuFluent is a neuroscience innovation venture studio with a platform-plus-initiatives architecture. The company operates across four core initiatives: Brain-Computer Interface (BCI) for direct brain-to-system communication and adaptive AI diagnostics; Pharmaceutical Technology for AI-enhanced drug delivery systems; Intelligent Implants & Robotics for smart implant and robotic surgical technologies; and Clinical Intelligence for AI-powered clinical data translation. These initiatives work together under one venture studio model that integrates neuroscience expertise, engineering, regulatory strategy, manufacturing, and commercialization to accelerate neurotechnology from concept to market.

Differentiator

Problem solved

Functional benefit

Products and services

• Brain-Computer Interface (BCI) Initiative Technologies enabling direct communication between the brain and external systems for neurological monitoring and treatment, including advanced AI diagnostics and adaptive treatments that learn and respond to each patient. Designed for innovators, clinicians, and healthcare systems seeking to develop or deploy next-generation BCI applications.
• Pharmaceutical Technology Initiative AI-based drug development and targeted delivery systems for neurological conditions, engineering AI-enhanced delivery systems that bypass traditional barriers and target disease directly at its source. Intended for pharmaceutical innovators and clinical research teams developing neurological therapies.
• Intelligent Implants & Robotics Initiative Next-generation smart implant technologies and enhanced robotic systems designed to transform neurological care and patient outcomes. Built for healthcare providers, neurosurgeons, and innovators developing active implant and surgical robotics technologies.
• Clinical Intelligence Initiative AI-powered technologies that translate clinical data into computational insights for next-generation healthcare applications, transforming how neurological disease is diagnosed, treated, and prevented. Designed for healthcare systems, clinical research organizations, and device developers leveraging large-scale clinical datasets.

Quantifiable outcome

• Over $20 billion in total return on investment
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and supporting.

• StarFish MedicalcoreOthersLeading North American medical device design firm; ISO 13485 certified; 25+ years experience; over 175 patents across cardiovascular, IVD, ophthalmology, optics, ultrasound, and neurological products. Part of NeuFluent's engineering team.
• Thompson Patent LawcoreOthersComprehensive IP strategy, patent prosecution, and portfolio management. Part of NeuFluent's Intellectual Property & Legal team.
• Fluent ManufacturingcoreOthersSpecialized medical device manufacturing and supply chain management. Part of NeuFluent's manufacturing team.
• OneNet Inc.supportingOthersCreative and digital agency for tech brands including Google, Uber, Lenovo; driven over $550M in attributed revenue; specializes in performance marketing, B2B SaaS, gaming, and digital entertainment. Part of NeuFluent's Marketing & PR team.
• Muto DigitalsupportingOthersFull-service digital agency specializing in web design, digital marketing, SEO, eCommerce solutions, and custom software development with bilingual capabilities. Part of NeuFluent's Marketing & PR team.
• LaBreche PRsupportingOthersAccomplished Fortune 500 executive and entrepreneur PR agency; worked with American Express, 3M, General Mills, Deloitte; former VP Enterprise Marketing at Fortune 100 CHS Inc.; expert in crisis communications and content strategy. Part of NeuFluent's Marketing & PR team.
• AM Public RelationssupportingOthersAward-winning boutique PR agency founded by Ashley Moore; specializes in healthcare, technology, aerospace/defense, climate/sustainability, and education sectors; expertise in highly regulated industries. Part of NeuFluent's Marketing & PR team.
• Ballard SpahrcoreOthersGeneral corporate and commercial legal services. Part of NeuFluent's Intellectual Property & Legal team.
• University of WashingtoncoreStrategic or Co-development PartnerAcademic partner institution where multiple NeuFluent team members serve as professors and leaders, including Dr. Sam Browd (Professor of Neurological Surgery) and Dr. Jeff Ojemann (Vice-Chair for Discovery and Professor of Neurological Surgery)
• Seattle Children's HospitalcoreStrategic or Co-development PartnerHealthcare partner where Dr. Jeff Ojemann serves as Senior Vice President and Chief Medical Officer, and where NeuFluent's BCI team includes neurosurgeon leadership

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Paradromics: Paradromics builds high-data-rate brain-computer interfaces for medical and communication applications. It is a direct peer in the implanted BCI category where NeuFluent is also investing.
• Neuralink: Neuralink develops implanted brain-computer interface systems for patients with paralysis and other neurological conditions. It is the most direct peer to NeuFluent's BCI initiative in target indication, technology category, and clinical pathway.
• Blackrock Neurotech: Blackrock Neurotech is a long-standing implanted BCI company with decades of human clinical experience in motor and communication restoration. It is a direct peer to NeuFluent's BCI initiative on both technology (electrode-array implants) and clinical use cases.
• Synchron: Synchron develops a minimally invasive stent-based brain-computer interface and has progressed to human clinical trials in the US and Australia. It competes head-to-head with NeuFluent's BCI program; one of NeuFluent's team members (Dr. Devapratim Sarma) has prior collaboration with Synchron.

Broad incumbents

• Medtronic: Medtronic operates one of the largest neurosurgery and neuromodulation portfolios in the world, including implantable neurostimulators, image-guided surgery systems, and drug delivery pumps. It is a broad incumbent competing with NeuFluent's Intelligent Implants & Robotics and Pharmaceutical Technology initiatives from a much larger commercial base.
• Brainlab: Brainlab is a global image-guided surgery, surgical planning, and digital health company serving neurosurgery, spine, and adjacent specialties. It is a direct adjacent peer to NeuFluent's implants/robotics and BCI surgical workflows; one NeuFluent team member (Ken Bruener) previously held global marketing and M&A roles at Brainlab.
• Stryker (Neurosurgery): Stryker's neurosurgery business includes image-guided navigation, surgical instruments, and cranial implants. It overlaps with NeuFluent's Intelligent Implants & Robotics initiative, particularly the minimally invasive spine and cranial surgery focus under Dr. Kevin Foley.
• Boston Scientific Neuromodulation: Boston Scientific's Neuromodulation division markets spinal cord and deep brain stimulation systems for neurological disorders. It competes with NeuFluent's intelligent implants initiative at the device-and-therapy intersection.

Emerging players

• MindMaze: MindMaze develops digital neurotherapeutics, brain-computer interface technology, and neurorehabilitation platforms. It overlaps with NeuFluent's BCI and neurorehabilitation-adjacent clinical intelligence applications, but is more focused on the digital-therapeutics delivery layer.
• Proprio: Proprio is an AI-enabled surgical navigation and visualization company co-founded by NeuFluent Co-CEO Dr. Sam Browd. It is a venture-portfolio-style peer that has historically come out of the same founder ecosystem as NeuFluent and competes in image-guided spine and neurosurgery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neufluent

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuFluent